Eric Rubin

Vice President of Oncology Clinical Research at Merck & Co.

Content by Eric Rubin:

 Research Field Cancer

Unlocking Checkpoint Inhibition

| Eric Rubin, David Matthews

Like many drugs today, pembrolizumab (Keytruda) was the result of a group effort. Here, we catch up with two scientists who shaped the destiny of the biotherapeutic at very different stages in its development.
Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register

October Issue of The Translational Scientist